Article Text

Download PDFPDF

2022-RA-466-ESGO Long-term responders (LTR) to rucaparib in recurrent ovarian cancer: a sub-group analysis from the rucaparib access (RAP) program in Spain by GEICO
  1. Alfonso Yubero1,
  2. Aranzazu Barquín2,
  3. Lydia Gaba3,
  4. Bella Pajares4,
  5. Piedad Reche5,
  6. Carmen Salvador6,
  7. Jesús Alarcón7,
  8. Luis Manso8,
  9. Raúl Marquez9,
  10. Jose Fuentes10,
  11. Julia Madani11,
  12. Manuel Costenla12,
  13. Maria Gutierrez-Toribio13,
  14. Purificacion Estevez-García14,
  15. Ana Santaballa15,
  16. Luisa Sanchez-Lorenzo16,
  17. Julia Calzas17,
  18. Ana Herrero18,
  19. Alvaro Taus19 and
  20. Antonio Gonzalez-Martin16
  1. 1Hospital Universitario Lozano Blesa, Zaragoza, Spain
  2. 2Centro integral oncológico Clara Campal, Madrid, Spain
  3. 3Hospital Clinic de Barcelona, Barcelona, Spain
  4. 4Hospital Universitario Virgen de la Victoria, Malaga, Spain
  5. 5Hospital de Torrecárdenas, Almería, Spain
  6. 6Hospital Lluis Alcanyis, Xativa, Spain
  7. 7Hospital Son Espases, Palma de Mallorca, Spain
  8. 8Hospital Universitario 12 de Octubre, Madrid, Spain
  9. 9MD Anderson, Madrid, Spain
  10. 10Hospital Universitario Virgen del Valme, Sevilla, Spain
  11. 11Hospital San Jorge, Huesca, Spain
  12. 12Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
  13. 13Hospital Araba-Txagorritxu, Vitoria, Spain
  14. 14Hospital Universitario Virgen del Rocío, Sevilla, Spain
  15. 15Hospital Universitari i Politecnic La Fe, Valencia, Spain
  16. 16Clinica Universidad de Navarra, Madrid, Spain
  17. 17Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain
  18. 18Hospital Universitario Miguel Servet, Zaragoza, Spain
  19. 19Hospital del Mar, Barcelona, Spain


Introduction/Background Rucaparib is a PARPi approved as maintenance (MTN) for platinum (Pt)-sensitive recurrent HGOC, and as treatment (Tx) for BRCA-mutated recurrent HGOC patients. Real-world data about LTR patients from the RAP is analyzed here.

Methodology A retrospective GEICO study was performed at 22 hospitals that treated patients within the RAP. Women with HGOC received rucaparib (600 mg BID) in the MTN, Tx Pt-sensitive or Tx Pt-resistant setting. In this subanalysis, long-term response was defined as progression-free survival (PFS) ≥12 months for the MTN group and ≥6 months for the Tx group.

Results In the study 51 patients were recruited: 18 received rucaparib as MTN and 33 as Tx.In the MTN group, 6 patients (33.3%) were LTR. Of them, 2 patients (33.2%) harbored BRCA or RAD51Cmutations. The median number of prior lines was 3 (2–6), being ≥5 in 33.2%, 66.6% had measurable disease and 50.0% achieved PR to prior Pt-based chemotherapy. In the Tx group, 10 patients (30.3%) were LTR. All of them harbored BRCA and/or RAD51C mutations. The median number of prior lines was 6 (2–9), with 60.0% receiving ≥5 prior lines, 60.0% were Pt-resistant and 60.0% had measurable disease. The median PFS of LTR was not achieved in the MTN group and was 10.9 months (95% CI: 7.0–16.7) in the Tx group. Adverse events (AE) of any grade were reported in 66.6% of LTR within the MTN group and in 100.0% within the Tx group, while AE of grade ≥3 occurred in 16.6% and 50.0%, respectively. No new safety signals were detected. At present, 3 and 1 patients are still receiving rucaparib as MTN and Tx, respectively.

Conclusion A durable response was achieved in a notable proportion of patients, despite their unfavorable conditions at treatment initiation. The safety profile of rucaparib in this real-world setting is consistent with that previously reported.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.